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Summary The aim of the study was to investigate expression of the active and inactive gelatinases (MMP-2 and -9) in colorectal neoplasia
and gastric cancer compared with normal mucosa. A total of 53 colorectal cancers and corresponding normal mucosa were studied using
gelatin zymography as well as 15 colorectal adenomas and 13 gastric cancers with corresponding normal mucosa. Overexpression of all the
gelatinases occurs in both colorectal and gastric cancer, with activation of MMP-2 appearing to be a feature of the malignant phenotype.
Overexpression of MMP-9 occurs in colorectal adenomas. The gelatinases are overexpressed in gastrointestinal neoplasia, suggesting that
these enzymes may have an important role in tumour invasion and metastasis.
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Matrix metalloproteinases (MMPs) are a family ofenzymes whose
main function is degradation of the extracellular matrix. These
enzymes are present in normal healthy individuals and have a role
in normal physiological processes (Jeffrey, 1991; Delaisse and
Vaes, 1992; Talhouk et al, 1992; Wolf et al, 1992; Wysocki et al,
1993). However, MMPs also act in pathological processes in
which breakdown ofthe extracellular matrix is a key feature. Such
diseases include rheumatoid arthritis (Harris, 1990), periodontal
disease (Page, 1991) and cancer.
MMPs have been functionally defined as having the following
characteristics: (1) they are proteinases that degrade at least one
component of the extracellular matrix; (2) they contain a zinc ion
and are inhibited by chelating agents; (3) they are secreted in a
latent form, requiring activation for proteolytic activity, (4) they
are inhibited by tissue inhibitors of metalloproteinases (TIMPs);
and (5) they share common amino acid sequences (Matrisian,
1990). There are currently 16 members of the MMP family
(Chambers and Matrisian, 1997) including the recently described
membrane-bound MMPs (MT-MMP) (Sato et al, 1994).
There has been a great deal of interest in the role of MMPs in
cancer (Parsons et al, 1997). Transformation of a tumour from the
benign to the malignant state involves both breakdown of the type
IV and V collagens that make up the basement membrane and
invasion through the underlying connective tissue stroma. Thus,
tumour cells infiltrate blood vessels and lymphatics, allowing
metastasis to a distant site. As these processes involve proteolysis
of the extracellular matrix and tissue remodelling, the MMPs have
been implicated in tumour progression (Liotta and Stetler-
Stevenson, 1990), with recent evidence suggesting that MMPs are
key regulators of the growth of tumours at both primary and
metastatic sites (Chambers and Matrisian, 1997). The gelatinases
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or type IV collagenases [72-kDa gelatinase (MMP-2) and 92-kDa
gelatinase (MMP-9)] are the enzymes that degrade the basement
membrane, and it is these enzymes that have been most studied.
Overexpression of MMPs has been demonstrated in a variety of
cancers including breast (Davies et al, 1993a; Brown et al, 1993b),
prostate (Wilson and Sinha, 1993), lung (Brown et al, 1993a),
bladder (Davies et al, 1993b) ovary (Naylor et al, 1994) head and
neck (Muller et al, 1993) and pancreas (Satoh et al, 1994). There is
also immunohistochemical and zymographic evidence indicating
that overexpression of MMPs occurs in colorectal and gastric
cancer (Parsons et al, 1997).
MMPs require activation in order to be biologically active.
MMP- I and -9 can be activated by the family of serine proteinases
(Suzuki et al, 1990; Okada et al, 1992) as well as by other
members of the MMP family (Sang et al, 1995; Parsons et al,
1997). However, MMP-2 activation is achieved only by MMPs
(Crabbe et al, 1994) with MT-MMP appearing to play an impor-
tant role (Sato et al, 1994; Parsons et al, 1997).
Inhibition of MMPs represents a potential mode of therapy for
gastric cancer, and the use of the orally active synthetic MMP
inhibitor Marimastat (British Biotech) in patients with inoperable
gastric cancer has undergone a phase I and II trial with encour-
aging results (Parsons et al, 1996). A phase III trial is currently
under way.
MMPs can be detected by a variety of complementary tech-
niques. Gelatin zymography has the advantages of measuring
direct enzymatic activity quantitatively (Kleiner and Stetler-
Stevenson, 1994) and ofdistinguishing the active from the inactive
enzyme (Brown et al, 1990; 1993b). In the present study gelatin
zymography has been used to measure MMP-2 and -9 expression
in colorectal tissue along the adenoma carcinoma sequence to
determine whether and at what point in colorectal progression
overexpression occurred. Activation ofMMPs is an important step
in vivo and therefore we attempted to determine at what stage in
the adenoma carcinoma sequence activation takes place. Expression
of MMP-2 and MMP-9 in gastric cancer compared with corres-
ponding normal mucosa was also studied.
14951496 SL Parsons etal
A
92 kDa _*
72 kDa-*
62 kDa =_
LANES 1 2 3 4 5 6 7 8 9 10
B
92 kDa _'
82 kDa -*
72 kDa* _v
62 kDa *
LANES 1 2 3 4 5 6 7 8 9 10
Figure 1 Examples of zymograms for colorectal carcinoma and corresponding normal mucosa are shown. Lane 1 contains 5 ng of standard gelatinase and
lane 10 contains 25 ng. Lanes 2-5 contain duplicate samples of normal mucosa followed by its corresponding carcinoma with a similar arrangement for lanes
6-9. The 92-, 82-, 72- and 62-kDa bands are marked
MATERIALS AND METHODS
Tissue samples
All solid tissue samples were cryopreserved in liquid nitrogen
following their removal from the patient and stored at -70°C. Up
to four 10-im sections were cut from the tissue using a cryostat
and the samples collected into an Eppendorf. Triplicate samples
were taken, one for protein determination and the remaining two
for zymography. Between 10 and 20 mg of tissue was used for
each sample as earlier work had shown this quantity of tissue to
give bands within the linear range ofthe zymogram. Sample buffer
(100 ,ul) was added to each zymography specimen and homoge-
nized. Ten minutes later the sample was centrifuged and 25 ,ul of
the supernatant was micropipetted into the wells of the precast
zymogram gels. Most specimens underwent separate histological
evaluation to confirm the presence of tumour or normal mucosa
respectively. All sections for zymography, protein determination
and histology were contiguous and gelatinase levels were
expressed per milligram of protein.
All colorectal cancers were classified by the Dukes' and the Jass
staging systems as well as the degree ofdifferentiation. Colorectal
adenomas were classified by the degree of dysplasia. Gastric
cancers were classified into degree of differentiation. All normal
mucosa samples were taken from the resected bowel or stomach
specimens but well away from the tumour.
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Figure 2 Straight line correlation of corrected integrated density with
gelatinase concentration. Correlation coefficient = 0.939 after correction for
intergel variation as described in the method
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Tablel 1Individual MMP values per milligram protein for colorectal cancer (tumour) and corresponding normal mucosa classified by Dukes' stage. Grade of
tumour, Jass classification and the presence of a lymphocyte infiltrate are also shown. A single case had preoperative radiotherapy and this case is listed
separately (A + DXT)
Patient Dukes' Mean normal/mg protein Mean tumour/mg protein Jass Lymphocyte Degree of
stage infiltrate differentiation
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B
B
B
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195.2
417.4
0
205.6
0
897.6
0
118.8
365.6
122.9
303.2
0
2854
0
286
195.2
638.8
74.9
825.9
138.6
734
0
2675
326.8
1434.4
0
9425.6
0
559.2
102
747.2
3494.8
1958
1863.2
0
638.8
711.6
1040.85
1494.4
1102.4
0
110.6
735.1
845.2
148.8
324.8
1606
139.2
116
5717.2
652
0
312.4
2772
681.8
A+DXT 408.4
116.5
180.1
68.8
91.2
0
66
62
166
288.8
0
205.6
286.8
110.4
148.8
244
116.5
156
18.1
162.1
113.6
99
93.7
187.8
523.2
543.2
389.6
1726
141.6
181.2
201.6
0
0
0
338.8
0
156
167.2
71.2
371.6
259.2
0
166.7
49.6
162.3
74
0
503.6
124
74.4
774.4
62.4
0
360
0
99.2
628.8
45.6
0
0
0
0
0
0
0
98
37.2
71.2
0
0
0
0
0
0
17.4
109.2
18.9
12.8
0
0
0
69.6
0
0
33.2
0
0
0
0
0
0
0
0
0
0
0
178.4
0
65.4
0
0
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0
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0
0
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374.8
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2510.8
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829.9
3300.1
4291.7
8240.9
803.2
2056
63482.4
4352
2836.8
16736.8
6192
5834.8
18502.4
11973.2
5093.4
68.4
82.5
260.8
0
187.2
0
542
532
202.8
182.4
254.8
862.4
844.4
420.8
40
202.8
116.4
192.8
145.2
546.5
381.1
267.4
1169.6
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956.4
1034
1001.2
585.6
336.8
528.4
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589.2
136.4
200
0
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Protein determination
Cold Tris-buffered saline (TBS; 200,l, pH 7.6) was added to the
frozen tissue and vortexed. Single detergent lysis buffer (SDL)
was then added (200 ltl) and the sample vortexed again. The
samples were left at 4°C for 30 min. Samples were then spun at
4°C in a microfuge at maximum r.p.m. for 5 min. The supernatant
was discarded and the pellet resuspended in 100 ,tl of cold SDL.
The samples were denatured at 100°C for 10 min and then cooled
to 4°C and stored at -20°C until assayed for protein.
The protein was determined in the samples using a Pierce kit
(Rockford, IL, USA). Standard bovine serum albumin (BSA) was
made up in TBS (pH 7.6) giving a concentration range 0.2-1.2 mg
ml-'. Buffer (10 ltl) of BSA standard or sample was pipetted into
each well. Protein assay reagent was added (200gl per well). The
plate was covered and incubated at 37°C for 30 min and the plate
was then read at 562 nm on the plate reader.
Gelatin zymography
Gelatin zymography was performed as previously described
(Heussen and Dowdle, 1980; Brown et al, 1993b) using commer-
cially available precast zymogram gels (Novex, R and D Systems).
Western blotting using monoclonal antibodies for MMP-9, pro-
MMP-2 and active MMP-2 was performed to verify that the
bands seen on zymography were as described (data not shown).
Quantification was performed using a flat bed scanner and the Apple
Macintosh software Adobe Photoshop and NIH Image as previously
described (Davies et al, 1993a; Kleinerand Stetler-Stevenson, 1994).
Pure gelatinase samples were obtained from British Biotech from
transfected Chinese hamster ovary cells (Chandler et al, 1995).
Quantification of zymography in our hands was determined
using serial dilutions of the pure MMP-2 gelatinase standard on
multiple zymograms (Figure 1). As the inactive pro-MMP-2
(72- kDa gelatinase) autoactivates to the active MMP-2 (62-kDa
gelatinase) in high concentrations, both these bands were combined
to give one value. Correction for variation in background staining
of the gel (intergel variation) was made by using the straight line
equation obtained for each zymogram to calculate the pixel value
for a single gelatinase value (15 ng) and correcting to the mean
value. Thus, a correction factor was obtained for each zymogram
allowing a single standard curve to be calculated after correction
for intergel variation (Figure 2). In all subsequent zymograms the
two outer lanes contained pure gelatinase standards at 5 ng and
25 ng respectively to allow correction for intergel variation. All
tissue samples were run in duplicate with tumour and corresponding
normal mucosa always studied on the same zymogram in order to
eliminate intergel variation as a source of error when comparing
expression in tumours vs normal mucosa. Examples ofzymograms
for tumour and normal specimens are shown in Figure 1.
Statistical analysis
All data were found to be non-parametrically distributed and
therefore the Wilcoxon signed-rank test was used for paired data
and the Mann-Whitney U-test for unpaired data.
RESULTS
Reproducibility of zymography
Computer-generated analysis of the MMP-2 bands from serial
dilutions of the pure MMP-2 gelatinase revealed a linear correla-
tion of integrated density (density multiplied by cross-sectional
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Figure 3 Expression of MMP-9 (A), pro-MMP-2 (B) and active MMP-2 (C)
in 53 paired colorectal cancers and corresponding normal mucosa and in 15
colorectal adenomas. Gelatinase concentration is measured as square pixels
per milligram protein. Median bars are shown. The 39 zero values for normal
mucosa in C are superimposed on each other
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area) with concentration ofgelatinase within the 0-50 ng range. A
correlation of 0.813 was obtained. The main source of variation
was due to differences in the background staining ofthe six zymo-
grams (intergel variation). Correcting for intergel variation using
the same standards on each zymogram gave a correlation coeffi-
cient of0.939 (Figure 2).
Colorectal cancer
Fifty-three fresh-frozen colorectal cancers and their corresponding
normal mucosa underwent zymography and protein determination.
Frozen haematoxylin and eosin (H&E) sections were prepared and
confirmed malignant cells of epithelial origin in all the cancer
specimens and normal epithelium in all the normal specimens.
There was a significant overexpression of the 92-kDa (pro-MMP-
9), 72-kDa (pro-MMP-2) and 62-kDa (active MMP-2) gelatinases
in colorectal cancer compared with corresponding normal mucosa
(P < 0.0001, P < 0.001, P < 0.0001 respectively) (Figure 3). As
can be seen from this figure there was expression ofpro-MMP-2 in
normal mucosa but virtually no expression of the active MMP-2
enzyme. The ratio of the active MMP-2 to pro-MMP-2 was 20-
fold higher in carcinoma than normal (ratio ofactive MMP-2)/pro-
MMP-2 = 0.08:1 for normal mucosa and 1.66:1 for carcinoma).
The 92-kDa gelatinase (pro-MMP-9) was overexpressed in
colorectal adenomas compared with normal mucosa (P < 0.0001)
but expression was less than in the carcinomas, although signifi-
cance was not obtained (P = 0.067, Figure 3A). The severely
dysplastic adenomas seemed to have the highest expression of
MMP-9, although the numbers were too small to perform mean-
ingful statistical analysis. There was no overexpression ofMMP-2
in adenomas compared with normal mucosa either for the pro-
MMP-2 or the active form (Figure 3B and C).
Colorectal cancers were subdivided by Dukes' stage, resulting
in 16 Dukes' stage A cancers, 19 Dukes' stage B and 18 Dukes'
stage C cancers. No statistically significant correlations between
Dukes' stage and gelatinase expression were seen.
Gelatinase expression was also correlated with the degree of
differentiation ofthe tumour and the Jass classification. No signif-
icant correlations were seen. Part of the Jass score includes the
presence or absence of a 'conspicuous peritumoral lymphocytic
infiltrate' (Jass et al, 1987). This latter parameter did not correlate
with MMP-9 expression. The MMP expression according to
pathological classification is shown in Table 1.
Gastric cancer
Sixteen gastric cancer and corresponding normal mucosa speci-
mens underwent zymographic analysis, protein determination and
H&E staining. In one of the normal mucosa specimens, histology
revealed tumour present in the sample and therefore this patient
was excluded. In two ofthe tumour sections there was no evidence
of tumour and therefore these two patients were also excluded. In
the sections of normal mucosa from three other patients there was
evidence of intestinal metaplasia in two cases and gastritis in one
case; these patients were included in the analysis.
There was a significant overexpression of the MMP-9 in gastric
cancers compared with normal mucosa (P < 0.005, Figure 4A).
There was no difference in the expression of the pro-MMP-2
between gastric cancer and normal mucosa (P = 0.89, Figure 4B)
but there was overexpression of the active MMP-2 (P < 0.02,
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Figure 4 Expression of MMP-9 (A), pro-MMP-2 (B) and active MMP-2 in 13
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samples are joined by a straight line and median bars are shown)
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Figure 4C). The ratio of active MMP-2 to pro-MMP-2 increased
over 30-fold in gastric cancer compared with normal mucosa (ratio
of active MMP-2: pro-MMP-2 = 0.04:1 for normal mucosa and
1.43:1 for carcinoma).
Expression of MMP-2 in normal mucosa was the same for
colorectal mucosa and gastric mucosa. However, expression of
MMP-9 was higher in gastric mucosa (median = 3743) than for
colorectal mucosa (median = 346, P < 0.001).
DISCUSSION
The most important finding of this study is that all the gelatinases
are significantly overexpressed in colorectal cancers compared
with their corresponding normal mucosa, and this evidence
supports the view that the gelatinases may play a crucial role in
colorectal cancer. This finding is consistent with other studies
looking at the expression of the gelatinases in colorectal cancer
(D'Errico et al, 1991; Hewitt et al, 1991; Pyke et al, 1993;
Gallegos et al, 1995; Zeng and Guillem, 1995; Liabakk et al, 1996).
In this study there was no statistically significant correlation
between gelatinase expression and any ofthe recognized measures
of tumour aggressiveness (Dukes' stage, degree of differentiation
and Jass classification). Only one previous study has shown a
correlation with Dukes' stage (D'Errico et al, 1991). In this
study immunohistochemistry was performed in 30 Dukes' A or
B cancers and 10 Dukes' C cancers, with a higher proportion
of Dukes' C tumours being positive for gelatinase.
Immunohistochemistry is not a quantitative technique and there-
fore these results should be treated with caution. A recent large
zymographic study showed a trend towards lower expression in
Dukes' B carcinoma compared with Dukes' A and C (Liabakk
et al, 1996). These differences were the opposite of our findings of
a trend towards higher expression in Dukes' B (data not shown),
and overall there is no strong evidence of altered expression with
Dukes' stage. MMP-9 expression showed no correlation with the
presence ofa lymphocytic and other inflammatory cell infiltrate as
defined by Jass et al (1987). MMP-9 is known to originate in
inflammatory cells (Hibbs et al, 1985; Pyke et al, 1993; Sang et al,
1995) and it has been suggested that MMP-9 expression simply
reflects the inflammatory infiltrate around the tumour rather than
the characteristics of the tumour itself. The lack of correlation
between MMP-9 and the lymphocytic infiltrate refutes this view.
The expression ofpro-MMP-2 (72 kDa) in normal mucosa seen
in this study is consistent with other work showing this enzyme to
be widely expressed in normal tissues, possibly because the MMP-
2 gene is known to be a 'house-keeping' gene (Matrisian, 1994).
The moderate increase in the expression of pro-MMP-2 along
the adenoma carcinoma sequence (Figure 3B) contrasts with
the dramatic change in active MMP-2, which is absent in non-
malignant tissue but increases dramatically on conversion to the
malignant phenotype (Figure 3C). This finding is consistent with
the other two zymographic studies on colorectal cancer (Yamagata
et al, 1991; Liabakk et al, 1996). This evidence supports the view
that activation of MMPs is a crucial step in tumour invasiveness
and clearer identification of the factors involved in this process
may open up new therapeutic options for the prevention and treat-
ment of malignant disease.
The active form of MMP-9 is the 82-kDa form. Unfortunately,
this band rarely appears as a detectable band on zymography and it
has been suggested that zymography is unable to differentiate the
92- from the 82-kDa band (Davies et al, 1993a). However, this is
clearly not the case, as, from our own studies and others, there is
occasionally a distinct band present (Figure IB; Brown et al,
1993b). It is more likely that the 82-kDa band is unstable and
undergoes further cleavage to smaller fragments, although no such
fragments were detected in the present study (Okada et al, 1992;
Woessner, 1995).
The finding that MMP-9 is overexpressed in colorectal
adenomas suggests that expression ofthis enzyme may be an early
step in the adenoma carcinoma sequence and that expression ofthe
enzyme continues to rise with progression along this sequence
(Figure 3A). Polyps that were severely dysplastic seemed to have a
high expression of MMP-9, although the numbers were too small
to perform any statistical analysis. In contrast to MMP-9, expres-
sion of MMP-2 was not increased in adenomas. Liabakk et al
(1996) found no gelatinase expression in adenomas and these
results conflict with our own. However, they have also shown no
expression of inactive MMP-2 in normal mucosa and, as they
admit in their discussion, it is likely that their technique is not
sensitive enough to detect the low levels of MMPs in non-malig-
nant tissue. Greater amounts of tissue per unit of sample buffer
were used in tissue preparation in the present study, and this may
explain the ability to detect gelatinase expression in normal
mucosa and adenomas. Other studies looking at gelatinase expres-
sion in colorectal adenomas were very small, with only occasional
expression seen (Newell et al, 1994; Zeng and Guillem, 1995).
No correlations of gelatinase expression with survival is
possible at present because of a limited follow-up period, and
these data are awaited. One study has found overexpression of
collagenase (MMP-1) to be associated with a poorer prognosis in
colorectal cancer (Murray et al, 1996), although no correlation of
survival with expression of gelatinase has yet been shown
(Liabakk et al, 1996).
Gastric cancer
MMP-9 and the activated form of MMP-2 are overexpressed in
gastric cancer with no change in the expression ofthe pro-MMP-2.
The reason why pro-MMP-2 does not appear to be overexpressed
may be due to the fact that most of the enzyme is converted to the
active form in the malignant phenotype, as in the case with
colorectal cancer. These results are consistent with larger recently
reported series (Nomura et al, 1995; Sier et al, 1996). In the former
study the expression of MT-MMP was studied in five of their
samples and a correlation between MT-MMP expression and acti-
vation of MMP-2 to the 62-kDa form was found. This evidence
suggests that MT-MMP may play a key role in the activation of
certain MMPs. The latter study showed that, although there was no
correlation of MMP expression with the established histological
classifications of gastric cancer, there was a correlation between
MMP expression and poor prognosis.
The numbers in this study were too small to draw any conclu-
sions in relation to tumour type or grade. Two large immunohisto-
chemical series have been reported evaluating the expression of
MMP-2 in gastric cancer. Both showed increased expression in
cancers compared with normal mucosa, and, whereas David et al
(1994) were unable to show any correlation with any pathological
features of the 87 tumours, Grigioni et al (1994) found a higher
incidence of MMP-2 in diffuse cancers than intestinal, and these
were associated with a worse prognosis.
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Expression ofMMP-9 was significantly higher in normal gastric
mucosa than in normal colorectal mucosa. It is interesting to note
that in the two specimens with the highest MMP-9 level, there was
either gastritis or intestinal metaplasia present on histology.
Gastritis implies the presence of inflammatory cells that could be
the source ofMMP-9 (Hibbs et al, 1985; Pyke et al, 1993) or these
may represent preneoplastic lesions with consequent overex-
pression of MMP-9 as is seen in the colorectal adenomas
(Figure 3A). The presence of these mucosal changes in a propor-
tion ofthe normal mucosa samples is a possible explanation for the
difference in expression of MMP-9 seen between normal gastric
and colorectal mucosa.
In conclusion, a clear relationship between overexpression of
the gelatinases and gastrointestinal malignancy has been demon-
strated. MMP-2 is not overexpressed in premalignant conditions
but conversion to the malignant phenotype is accompanied by
overexpression of the inactive enzyme and, more importantly,
cleavage to the active form. In contrast, MMP-9 is overexpressed
in premalignant polyps, suggesting that this enzyme is expressed
earlier on in the adenoma carcinoma sequence. This evidence
suggests that inhibition ofthe MMPs may form a useful method of
treating gastrointestinal malignancy.
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